Abstract
The rheumatic disorders reviewed in this chapter are characterized by tissue damage resulting from self-reactivity mediated by abnormal immunologic activation. The underlying pathophysiology involves a failure of the complex regulatory mechanisms of the immune system that enable distinguishing “self” from “non-self.” Many rheumatic diseases occur predominantly in women of reproductive age. The immunological and hormonal alterations of gestation may influence rheumatic disease activity, and rheumatic disease activity may be associated with poorer pregnancy outcomes. Moreover, some autoimmune conditions clearly predispose to adverse pregnancy outcomes such as fetal death or poor placental vascularization leading to preeclampsia or placental insufficiency. Treatment of rheumatic disease in pregnancy poses yet another challenge and requires well-coordinated, interdisciplinary care. In his chapter, we summarize the implications and management of systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, and systemic vasculitis in pregnancy. We have also profiled the potential risks and benefits in pregnancy of the most commonly used antirheumatic drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
